

05 August, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400001,
Maharashtra, India

The National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400051,
Maharashtra, India

Scrip Code: 540975**Scrip Symbol: ASTERDM**

Dear Sir/Madam,

Sub: Investor Presentation for the quarter ended 30 June 2026

Ref: Our letter dated 31 July 2026, and Regulation 30 read-with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the captioned subject, please find enclosed the Management's Presentation for the Earnings Conference Call with analysts/ Investors scheduled for 5 August 2026 in relation to the unaudited financial results for the quarter ended 30 June 2026.

Kindly take the above-said information on record.

Thank you

**For Aster DM Quality Care Limited
(Formerly Aster DM Healthcare Limited)**

HEMISH
PURUSHOTTAM

Digitally signed by
HEMISH PURUSHOTTAM
Date: 2026.08.05
17:29:22 +05'30'

Hemish Purushottam

Company Secretary and Compliance Officer
M. No. A24331

Aster DM Quality Care Limited
(Formerly Aster DM Healthcare Ltd.)

Registered Office: No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev
Reddy Nagar, Ameerpet, Hyderabad, Telangana, India, 500038

Corporate Office: Brigade Deccan Heights 20th & 12th Floor,
#42, 5th Mile, Tumkur Rd, Yeshwanthpur Industrial Area, Phase 1,
Yeshwanthpur, Bengaluru, Karnataka, India, 560022

CIN: L85110TS2008PLC207383
Telephone: +91 96060 61833
E-mail: cs@asterqualitycare.com
Website: www.asterqualitycare.com

Earnings Presentation Q1 FY27



Aster DM Quality Care Limited

Disclaimer

- This presentation has been prepared by Aster DM Quality Care Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. Subsequent developments may impact the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. Contents in the Presentation do not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.
- Prospective and existing investors should make their own evaluation of the Company as the information provided here does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. Interested parties shall conduct their own due diligence and investigation on the information, before relying and acting thereon. Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company.
- This presentation may contain certain "forward looking statements", which are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Though such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

Note - Quality Care numbers are indicative and subject to statutory audit adjustments. Proforma numbers for combined entity are also subject to finalization and audit of the merged accounts. Actual amounts, losses or impact on net profit could materially differ from those that have been estimated. In addition, other factors that could cause actual results to differ materially from those estimated include harmonization of accounting policies and practices.

Merger became effective on July 1, 2026 forming Aster DM Quality Care Limited

Executed on schedule with zero operational friction, establishing the cultural foundation required to unlock long-term financial synergies



#GO GREATER
Building one culture across the combined organisation
Guided by 8 tenets. United by purpose



On Time 

Merger Execution

Merger completed on schedule reflecting our disciplined execution

41+ 

Sites

Hospitals & offices covered with zero service disruption.

4,000+ 

Key Leaders Aligned

Doctors & senior executives engaged through leadership webinar on day - 1


45,000+ 

Celebration Kits Delivered

Enterprise-wide adoption of single brand & operating framework.

A structured cultural integration programme driving employee engagement, shared behaviors & long-term integration success

Creating a larger platform to make quality healthcare accessible



28
Cities

9
States

39²
Hospitals

321
Labs & PECs³ and
205⁴ Pharmacies

7,400+
Doctors⁵

37,700+
Workforce⁵

~8.0 Mn⁶
Total Patient Volume

Notes:

- 1. Presence and Operational metrics are as on June 30, 2026
- 2. Including WIMS. Count includes 4 O&M Asset Light hospital beds with a capacity of 608 beds
- 3. PECs: Patient Experience Centers
- 4. Pharmacies in India operated by ARPPL under brand license from Aster
- 5. Including outsourced Employees, as on Mar'26
- 6. On TTM Basis
- 7. Kerala hospital and bed count excludes WIMS

Strategic rationale behind the merger



Aster DM Quality Care Proforma Performance Highlights

Operational Beds

Q1FY27 : 10,559

Q1FY26 : 10,193

▲ 366

Total Patients Volume

Q1FY27 : 2.01 Mn

Q1FY26 : 1.78 Mn

▲ 13%

ALOS (Days)

Q1FY27 : 3.40

Q1FY26: 3.47

▼ 2%

ROCE³

Q1FY27 : 22.9%

Q1FY26: 20.4%

▲ 246 bps


The Combined Entity¹ demonstrates Strong YoY Revenue Growth aided by Steady Patient Volume growth

- 20% YoY growth in Revenue, reaching INR 2,597 Cr in Q1FY27 driven by 13% growth in patient volumes led by Neurosciences, Oncology, Orthopedics and Gastroenterology
- ARPP IP grew by 10% YoY to INR 1,36,802 driven by growth in high-end tertiary procedures, like robotic, transplants and joint replacements
- Medical Value Travel (MVT) has grown by 62% supported by addition of new geographies


Robust EBITDA Growth Reflecting Operational leverage and Effective Cost Management; Improvement in RoCE Reflecting better asset utilisation

- The merged entity¹ delivered robust 30% YoY EBITDA² growth to INR 576 Cr in Q1FY27 driven by strong revenue growth and disciplined cost management
- EBITDA² margin increased by 170 bps to 22.2% in Q1FY27 driven by efficiency in material consumption and better absorption of fixed costs
- RoCE³ increased by 246 bps reaching 22.9% in Q1FY27 due to EBITDA upside
- The newly operationalised Kasargod Hospital achieved EBITDA breakeven in June, within nine months of launch
- Commissioned 159-beds at "Aster Women & Child" block at Aster Whitefield in April 2026

Revenue from Operations (INR Cr)




Operating EBITDA² (%) (INR Cr)



Ex. new unit⁴ Up 31% YoY to INR 578 Cr

Operating EBITDA Margin² (%)



Ex. new unit⁴ Up 190 bps to 22.4%

1. Proforma Basis.

2. Combined Operating EBITDA is Post INDAS EBITDA adjusted for one off expenses, ESOP cost, movement in fair value of contingent consideration and variable Q&M fee

3. RoCE is computed on average capital employed excl. revaluation reserves and CWIP and Intangibles

4. New unit: Kasargod

Combined Proforma Numbers for Q1FY27

(Figures for Q1FY27)

Aster + Quality Care ¹ = Merged Entity*				
Financial Metrics				YoY Growth
	Revenue (INR Cr)	1,311	1,287	2,597 20%
	Operating EBITDA ² (INR Cr)	277	299	576 30%
	Op EBITDA Margin %	21.1%	23.2%	22.2% 170 bps
	ROCE ³ (%)	22.6%	23.1%	22.9% 246 bps
	Net Debt (INR Cr)	(511)	1,673	1,162

* Proforma financials for combined entity are subject to finalization and audit of the merged accounts. Actual amounts, losses or impact on net profit could materially differ from those that have been estimated. In addition, other factors that could cause actual results to differ materially from those estimated include harmonization of accounting policies and practices.

1. Quality Care numbers are indicative and subject to statutory audit adjustments, if any
2. Combined Operating EBITDA is Post INDAS EBITDA adjusted for one off expenses, ESOP cost, movement in fair value of contingent consideration and variable O&M fee
3. RoCE is computed on average capital employed excl. revaluation reserves and CWIP and Intangibles

Combined Proforma Numbers for Q1FY27

(Figures for Q1FY27)

		Aster	+	Quality Care ¹	=	Merged Entity*		
Operational Metrics	No. of Hospitals (Nos)	20 ¹		19		39		
	City Presence (Nos)	16		14		28		
	Operational Beds ² (Nos)	5,385		5,174		10,559	↑ 3.6%	
	Occupancy (%)	62%		65%		64%	↑ 510 bps	
	Total Patient Volume (Mn)	1.03		0.98		2.01	↑ 13%	


* Proforma financials for combined entity are subject to finalization and audit of the merged accounts. Actual amounts, losses or impact on net profit could materially differ from those that have been estimated. In addition, other factors that could cause actual results to differ materially from those estimated include harmonization of accounting policies and practices.

1. Includes WIMS
2. Capacity beds grew from 10,288 to 10,898 as on June 30, 2026


Aster DM Quality Care Overview

Hospitals & Clinics Revenue Mix Q1FY27

Payor Revenue Mix



Specialty-wise Revenue Mix



1. MVT: Medical Value Travel
2. Numbers in brackets are for corresponding quarter prior year

Aster DM Quality Care: Q1FY27 Clinical Highlights

Our Clinical Excellence

- Kerala’s 1st transcatheter Fontan procedure performed at Aster Medcity, Kochi
- Karnataka’s 1st robotic-assisted revision knee replacement using CORI system at Aster RV, Bengaluru
- Highest number of Lymph Venous Anastomosis in a single institution in India at Aster Whitefield, Bengaluru
- 1st and largest Robotic Hepatic Artery Infusion (HAI) therapy, in India for non-curable liver metastases
- Neurosciences department at Aster Whitefield hospital has successfully completed 2,000 Brain and Spine Surgeries in less than 2 years

Expanding the Reach of Advanced Care

- High-risk multidisciplinary surgery performed for Stage IV colon cancer with liver metastasis at KIMSHEALTH Nagercoil
- Parenchyma-preserving bronchus intermedius sleeve resection milestone achieved at MIMS Kannur
- Critical neonate with pulmonary hemorrhage and severe PAH successfully stabilized and discharged at KIMSHEALTH Trivandrum
- First minimally invasive multivessel CABG performed at unit for high-risk comorbid patient at CARE Vizag

Accreditations



Transforming Lives Through Clinical Excellence¹



87,125+
Cardiac Procedures



11,685+
Neuro Procedures



4,780+
Robotic Surgeries



9,215+
Joint Procedures



885+
Transplants
(Renal, Liver & Heart)

Clinical Infrastructure



58
Cathlabs



14
LINACs















34
MRI machine




23
Robots

1. Surgery counts are on TTM basis and proforma basis

Maturity Wise Hospital Performance: Q1FY27

Maturity	Operational Beds ⁵	Key Performance indicators		
		Revenue ⁶ (INR in Cr)	Operating EBITDA ⁶ (INR Cr)	Operating EBITDA % ⁶
Mature ¹	 65%	 73% ↑ 19%	 86% ↑ 29%	29.7%
Focus ²	 14%	 15% ↑ 16%	 10% ↑ 20%	16.8%
Emerging ³ Hospitals	 10%	 6% ↑ 63%	 3% ↑ 240%	12.4%
Under ⁴ Performing	 11%	 5% ↑ 28%	 1% ↑ 422%	3.6%
	10,559	2,535 ↑ 21%	639 ↑ 31%	25.2%

1. Mature: Units aged more than 3 years, with EBITDA margin of 25% or higher
2. Focus: Units aged more than 3 years, with EBITDA margin of 15–25%
3. Emerging: Units aged 0–3 years
4. Under Performing: Units aged more than 3 years, with EBITDA margin below 15%
5. Total Operational Beds are beds as on 30th Jun, 2026.
6. Revenue and Operating EBITDA shown above are of Hospitals and Clinics only and excludes other business and corporate cost
All numbers above exclude Wayanad Institute of Medical Sciences (WIMS). Maturity cut will be reviewed on annual basis.



Board of Directors



Dr Azad Moopen
Executive Chairman



Varun Khanna
Managing Director and
Group CEO



Alisha Moopen
Executive Director



Ayshwarya Vikram
Non-Executive Director



Ganesh Mani
Non-Executive Director



James Mathew
Independent Director



Kewal Handa
Independent Director



Neeraj Jain
Independent Director




P H Vijaya Deepti
Independent Director



**Sunil Theckath
Vasudevan**
Independent Director



T.J. Wilson
Non-Executive Director



VK Mathews
Independent Director

Leadership Team



Varun Khanna

Managing Director &
Group Chief Executive Officer



Sunil Kumar M R

Group
Chief Financial Officer



Hemish Purushottam

Company Secretary and
Compliance Officer



Ramesh Kumar

Chief Executive Officer
(India I)



Dr. Pawan Kumar

Chief Executive Officer
(India II)



Vishal Maheshwari

Chief Executive Officer
(India III)



**Dr. Ratnadeep
Chaskar**

Chief Executive Officer
International



Hari Prasad VK

Chief Internal Audit and
Risk Management Officer



Richa Singh

Chief Legal Officer



SV Kiran

Group
Chief People Officer



Dr. Somashekhar SP

Group
Medical Director



Sudeep Dey

Chief Information Officer



T J Wilson

Director and Head -
Integration, ESG and CSR



Vinod Raman

Chief Digital Officer

Awards, Rankings & Ratings



Dr. Azad Moopen
Executive Chairman

- Lifetime Achievement Award by Financial Express
- ET Entrepreneur Awards - Global Entrepreneur of the Year
- ET Healthcare Awards - Healthcare Icon of the Year
- Entrepreneur India - Lifetime Achievement Award
- Mount Judi – Lifetime Achievement Award



Ms. Alisha Moopen
Executive Director

- ASSOCHAM Awards 2026 – Women Leader in Business
- Ranked 4th among Top Women Leaders and listed in Top 100 Successors List 2026 in the Hurun India ASK Private Wealth List
- ET Family Business Awards - NexGen Business Leader
- Fortune India - Featured in 100 Most Powerful in Business



Dr. M I Sahadulla
Chair - Medical Advisory Board

- Lifetime Achievement Award by Financial Express
- Legend in the Healthcare Industry - FICCI HEAL
- Lifetime Achievement Award - CAHO



Ranking

Aster Hospitals shines in Newsweek's 2026 World's Best Hospital Rankings

Aster CMI	12 th
Aster Medcity	28 th
Aster RV	58 th
Aster MIMS	71 st



The Best Brand Award-
Aster DM Healthcare

The Best Brand Award-
CARE Hospitals

The Best Brand Award-
KIMSHealth



Best Multispecialty Hospital, India

Aster Medcity
Aster CMI Aster
MIMS

Times of India Critical Care Ranking 2026 - Centres of Excellence of

Aster Medcity, Aster CMI, and Aster MIMS featured in All India Top 10 Ranking



KIMSHEALTH Trivandrum is ranked No.1 in the category of Best Multi-Specialty Private Hospital (November 2025)



Aster DM Healthcare has been awarded Excellence in Mergers & Acquisitions by Business World



Aster Digital Health won 'Most Impactful Digital Transformation in Healthcare' at the Elets Technomedia Healthcare Innovation Awards 2025



Dun & Bradstreet Recognised
Aster among India's Top 500 Value Creators

Outlook

National Ranking Best Hospital

Aster Medcity	2 nd
Aster CMI	4 th
Aster MIMS	8 th
KIMS Health, Trivandrum	3 rd
Care Banjara Hills	7 th



1st Prize in the Central Zone Sustainability Award: Care Hospitals




Fortune Leadership Award 2025 for Best Volunteer Engagement



KIMS health Received FE award in June 2026 for Excellence in Multi-Specialty Care (National) and Excellence in Cardiac Care (South India)

Multiple avenues of synergies poised to accelerate growth and profitability




Well positioned to unlock value through synergies and deliver 10–15%¹ EBITDA uplift

1. As % of FY24 Pro-forma EBITDA of the merged entity

Planned Expansion across Aster DM Quality Care

Addition of 4,179 beds, bringing the total bed capacity to 15,077 beds



Aster DM - Performance Highlights Q1FY27

Aster: Key Highlights for Q1FY27

Strong 22% YoY growth in Revenue led by robust performance across Core Hospital & Clinics

- Driven by higher patient volumes, stronger specialty and payor mix, clinician additions and the ramp-up of Kasargod
- Mature units (~77% of revenue) saw a revenue growth of 19% YoY, supported by increase in patient volumes and improved case mix across Oncology and Neurology
- Revenue in emerging units (~5% of revenue) grew 95% YoY, driven by ramp up of Kasargod facility
- Focused Units (~13% of revenue) grew 19% YoY, with operationalization of newly added beds in the quarter

29% YoY Operating EBITDA growth driven by combination of strong revenue growth, operating leverage, and disciplined cost management.

- Revenue growth of 22% drove operating leverage, while Kasargod's nine-month breakeven further boosted EBITDA
- Enhanced cost efficiencies across material and other operating costs supported EBITDA growth
- EBITDA growth aided by strong performance of mature and emerging hospitals, driven by focused operational initiatives and better fixed cost absorption

Occupancy improved by 350 bps (from 59% to 62%) led by higher IP volume growth

ALOS improved by 4% to 3.0 days aided by increased robotics surgeries and efficient hospital operations

ARPP IP rose by 10% supported by healthy payor mix and increase in CONGO Revenue by 23% YoY

- Growth in high-end tertiary care, with robotic cases up 80%, bone-marrow transplants up 80%, kidney transplants up 55% and joint replacements up 27%

Medical Value Travel (MVT) which grew by 72% YoY aided by improving international patient inflows and stronger referral networks

- Led by the Maldives and GCC markets, with a growing contribution from Africa, other MENA countries and the rest of SAARC

Aster DM Healthcare Limited conferred with 'Healthcare Brand of the Year' by Economic Times 2026

Aster: Performance Highlights for Q1FY27

Financial

Revenue¹

Q1FY27 : INR 1,311 Cr

▲ 22%

Q1FY26 : INR 1,078 Cr

Q1 FY27 (ex-new unit⁴) >

Operating EBITDA^{1,2}

Q1FY27 : INR 277 Cr

▲ 29%

Q1FY26 : INR 215 Cr

Up 30% YoY to INR 279 Cr

Op EBITDA Margin^{1,2}

Q1FY27 : 21.1%

▲ 117 bps

Q1FY26 : 20.0%

Up 170 bps to 21.7%

RoCE³

Q1FY27 : 22.6%

▲ 190 bps

Q1FY26 : 20.7%

Up 350+ bps to 24.2%

Operational

Operational Beds

Q1FY27 : 5,385

▲ 366

Q1FY26 : 5,019

ARPP IP

Q1FY27 : 1,30,352

▲ 10%

Q1FY26 : 1,18,011

ALOS (Days)

Q1FY27 : 3.0 days

▼ 4%

Q1FY26 : 3.1 days

Total Patient

Q1FY27 : 1.03 mn

▲ 16%


Q1FY26 : 0.89 mn

1. Revenue, Operating EBITDA and EBITDA excludes other income.
2. Operating EBITDA for Q1 FY27 excludes ESOP Cost of: INR 2.45 Cr [Q1 FY26: 0.82 Cr], Variable O&M fee amounting to INR 10.44 Cr [Q1 FY26: 7.16 Cr].
3. ROCE = EBIT/Average Capital Employed; [Capital employed excludes CWP, Land Revaluation reserve and Investment in QualityCare
The CWIP for ongoing projects (including ROU, Capital Advances, and Capital Creditors) is INR 1,238 Cr for Q1 FY27 [Q1 FY26: 1,057 Cr].
4. New unit: Kasargod


Aster: Revenue Mix Q1FY27

Q1FY27 [Q1FY26]


Segmental Revenue Mix




Specialty-wise Revenue Mix¹



Geographical Revenue Mix¹



Payor Revenue Mix¹



1. Refers to the revenue from hospitals only | 2. MVT: Medical Value Travel | 3. Numbers in brackets are for corresponding quarter prior year

Aster : Profitability Statement

Particulars	Q1FY27	Q1FY26	YoY %
Revenue from Operations	1,311	1,078	22%
Gross Profit	1,019	831	23%
Gross Profit Margin (%)	77.7%	77.1%	
Operating EBITDA	277	215	29%
Operating EBITDA Margin (%)	21.1%	20.0%	
EBITDA Post INDAS	264	207	27%
EBITDA Post INDAS Margin (%)	20.2%	19.2%	
Profit Before Tax	201	147	37%
PBT Margin (%)	15.3%	13.6%	
Normalised PAT ² (Post NCI) ³	125	90	39%
Normalised PAT ² Margin	9.5%	8.3%	
EBITDA Pre INDAS	232	181	28%

Revenue

- Grew by 22% YoY in Q1FY27 driven by higher patient volumes, improved realizations, a stronger specialty and payor mix, doctor additions and the ramp-up of Kasargod.

Gross Profit

- 23% YoY growth in Gross Profit on account of the leverage from **material cost reduction by 67 bps**, supported by continued procurement efficiencies and ongoing cost-optimisation initiatives across key procedures

Operating EBITDA

- 29% YoY Operating EBITDA growth which is higher than revenue growth with the leverage from disciplined cost management
- Operating cost (doctor & employee cost and other cost) **reduced by 50 bps**, supported by fixed-cost absorption and ongoing efficiency initiatives

PAT

- Normalised PAT² (post NCI) grew 39% to 125 Crs in Q1FY27

1. Above numbers are in INR Cr
2. The Normalised PAT for Q1 FY27 excludes exceptional expenses of INR114.4 Cr (Q1 FY26: INR 4.4 Cr)(merger related costs).
3. Non-Controlling Interest

Geography wise Business: Snapshot for Q1FY27

Kerala^{1,2}

Revenue

INR 687 cr

▲ 25% YoY

54%

Capacity Beds	2,988
Operational Beds	2,912
Occupancy ³	64%
ALOS (days)	2.7
IP Volume Growth	▲ 16%
Total Patient Growth	▲ 19%
ARPP IP	INR 1,12,610 ▲ 10%

Karnataka & Maharashtra¹

Revenue

INR 432 cr

▲ 16% YoY

34%

Capacity Beds	1,579
Operational Beds	1,438
Occupancy ³	60%
ALOS (days)	3.2
IP Volume Growth	▲ 5%
Total Patient Growth	▲ 6%
ARPP IP	INR 1,95,022 ▲ 13%

Andhra & Telangana¹

Revenue

INR 157 cr

▲ 33% YoY

12%

Capacity Beds	1,157
Operational Beds	1,035
Occupancy ³	60%
ALOS (days)	3.7
IP Volume Growth	▲ 18%
Total Patient Growth	▲ 19%
ARPP IP	INR 99,874 ▲ 15%

1.

Data for hospitals only

2.

Data excludes WMS

3.

Occupancy is calculated based on Operational Beds (Census).

'Women & Children' Facility - Aster Whitefield, Bengaluru

Expansion aligned with rising demand for high-quality maternal & pediatric care



Key Highlights



Commissioning

Women & Child unit (Block D) successfully **inaugurated in April'26**



In Presence of

Inaugurated in the presence of **Shri Dinesh Gundu Rao**, Hon'ble Minister of Health & Family Welfare, Govt. of Karnataka, and **Shri U.T. Khader**, Hon'ble Speaker, Karnataka Legislative Assembly.



Investment & Scale

INR 96 Cr investment
Total Capacity expanded from **377** to **536** beds
159-bed specialized facility added



Comprehensive Care Offering

- Level 3 NICU
- Neonatal & paediatric surgical services
- Fertility center
- PICU & HDU
- Advanced Laparoscopic Gynaec Surgery
- Aesthetic & Cosmetic Center
- Foetal Medicine
- End-to-End Maternity Care
- Child Development Center
- Water Birthing



A state-of-the-art facility delivering compassionate care and clinical excellence for healthier mothers and happier children.

12+ YEARS
OF CARE IN BENGALURU

Quality Care Performance Highlights

Quality Care: Key Highlights for Q1FY27

Strong 19% YoY revenue growth for the business driven by robust performance across clusters

- Growth driven by higher IP Volumes, favorable shift in payor mix toward cash and insurance and increased share of complex procedures associated with strong clinical hiring
- Mature Units (~69% of revenue) registered a revenue growth of 18% YoY led by 10% volume growth
- Revenue in Emerging Units (~7% of revenue) grew 47% YoY aided by newly hired doctors and new corporate/insurance tie ups
- Focused Units (~17% of revenue) grew 13% YoY through continued focus on clinician engagement in competitive local markets, and driving higher OP and IP footfalls

Overall operating EBITDA grew by 32% YoY largely driven by higher topline growth, operational excellence initiatives and better leverage

- Robust EBITDA growth led by higher revenue growth of 19%
- Operating leverage in material cost and Doctor cost through increased patient footfalls, improved case mix including complex procedures and a favorable payor mix
- EBITDA growth also driven mainly by strong performance from improved volumes and efficiencies, and rapid turn around in emerging units which have started to contribute favourably towards EBITDA

Occupancy improved by 656 bps (from 58.9% to 65.4%) led by higher IP volume growth

9% YoY growth in IP ARPP, reaching ~INR 144k in Q1FY27 driven by deeper clinical mix, robust growth in robotic, joint replacement and transplants along with better payor mix

- 100% growth in robotic procedures, 41% in Joint replacement along with 42% increase in Transplants
- Share of Cash and Insurance business improved by 50 bps on a YoY basis
- ARPP growth supported by better performance from surgical specialities namely Neuro, Ortho and transplants

Strengthened clinical teams by onboarding 50+ doctors across the hospital network contributing ~9.5 Cr in monthly revenue

CARE Hitech secured JCI accreditation, becoming the 1st unit in CARE network

Quality Care : Performance Highlights for Q1FY27



Quality Care numbers are unaudited and subject to audit adjustments;
1. Operating EBITDA is post-IndAS EBITDA adjusted for one-off expenses;
2 RoCE is computed on average capital employed excl. revaluation reserves and CWIP and Intangibles

Annexure

Merged entity with robust revenue growth and strong margin profile



* Proforma numbers for merged entity are subject to finalization and audit of the merged accounts. Actual amounts, losses or impact on net profit could materially differ from those that have been estimated. In addition, other factors that could cause actual results to differ materially from those estimated include harmonization of accounting policies and practices.

1.

2.

3.

4.

Financials reflect Quality Care consolidated proforma metrics, including CARE Hospitals, KIMSHEALTH and Evercare. The acquisition of KIMSHEALTH was completed in Q4 FY24

Quality Care Historical financials have been converted at a different exchange rate vis-à-vis FY25

All numbers of Quality Care are indicative and subject to statutory audit adjustments, if any

Combined Operating EBITDA is Post-INDAS EBITDA adjusted for one-time & non-cash expenses, ESOP cost, movement in fair value of contingent consideration and variable O&M fee



THANK YOU

